Cite
HARVARD Citation
Fizazi, K. et al. (n.d.). 805PA phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic (M0) castration-resistant prostate cancer (CRPC): Results of PROSPER by age and region. Annals of oncology. p. . [Online].